Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Autor: Beran J; Department for Tropical, Travel Medicine and Immunization, Institute of Postgraduate Health Education, 100 05 Prague, Czech Republic., Špajdel M; Department of Psychology, Faculty of Philosophy and Arts, Trnava University, 918 43 Trnava, Slovakia., Slíva J; Department of Pharmacology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2021 Nov 09; Vol. 13 (11). Date of Electronic Publication: 2021 Nov 09.
DOI: 10.3390/v13112246
Abstrakt: Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein-Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup.
Databáze: MEDLINE